Who Actually Builds the Market Access Dossier Before a Drug Launches

Introduction

A new drug can clear every regulatory hurdle — approval in hand, label finalized, manufacturing validated — and still sit on a shelf commercially if no payer will cover it. That gap between regulatory approval and actual patient access is where the market access submissions specialist works, building the dossier that convinces health technology assessment (HTA) bodies and payers that a product is not just safe and effective, but worth what it costs. It's one of the less visible roles in the launch sequence, largely because its output rarely gets discussed outside of pricing and reimbursement committees, but almost no major drug launch happens without someone doing this job.

This piece lays out what the role actually involves, how it differs from both pure regulatory affairs work and pure health economics work, and what it takes to move into it.

What a Market Access Dossier Actually Contains

At the center of the role is the global value dossier (sometimes called a value communication package or, in the US context, an AMCP-format dossier submitted to payers and pharmacy benefit managers). This is not a regulatory submission in the FDA or EMA sense — it isn't seeking approval to market the product — but it draws heavily on the same underlying clinical data, repackaged and extended for a different audience and a different question.

A typical dossier needs to answer, with evidence a payer or HTA body will actually trust:

• How does this product perform against the relevant standard of care, not just against placebo? This often requires indirect treatment comparisons or network meta-analyses when head-to-head trial data doesn't exist.
• What is the health economic case — cost-effectiveness modeling, budget impact analysis, and quality-adjusted life year (QALY) estimates where applicable — for covering this product at the proposed price?
• What real-world evidence, patient-reported outcomes, or long-term follow-up data supports claims the pivotal trial alone can't fully establish?
• How does the product's value story differ across jurisdictions — what the UK's NICE wants to see is not identical to what Germany's G-BA wants, or France's HAS, or a US payer's P&T committee, and the dossier has to flex to each audience without contradicting itself.

Building this requires pulling together clinical trial data, health economics models (often built by a separate HEOR team or outside consultancy), competitive intelligence on comparator products and their pricing, and increasingly, patient and caregiver input, into a single, internally consistent narrative that will be picked apart by skeptical, technically sophisticated reviewers.

Where This Role Sits Between Regulatory Affairs and Health Economics

It's easy to assume this is just regulatory affairs work under a different name, or just health economics and outcomes research (HEOR) work with a submissions deadline attached. It's neither, exactly, and the distinction matters for anyone considering the move.

Regulatory affairs is concerned with whether a product can be marketed at all, built around a dialogue with agencies like the FDA or EMA about safety and efficacy against a defined standard. Market access submissions assume the product will be, or already has been, approved, and are concerned with a completely different question: whether a payer should cover it, and at what price relative to its demonstrated value. The clinical data is the same starting material, but the argument built from it is different, and so is the audience's training — an HTA reviewer is often as comfortable with statistics and economic modeling as a clinical reviewer is with trial design.

HEOR teams, meanwhile, typically build the economic models and generate the real-world and comparative-effectiveness evidence that go into a dossier, but they aren't always the ones responsible for packaging that evidence against each market's specific submission requirements, sequencing it against the regulatory and commercial launch timeline, and managing the actual HTA or payer-facing process. That coordination and translation function — knowing what NICE's submission template requires versus what a US payer's formulary committee expects, and making sure the underlying evidence satisfies both — is the market access submissions specialist's specific territory.

In practice, the role functions as a bridge: literate enough in clinical trial design to use the data correctly, literate enough in health economics to understand what the models are actually claims, and skilled enough at regulatory-style document management and timeline coordination to keep a multi-market submission process from falling apart under its own complexity.

Why the Timing Matters So Much

One of the most distinctive features of this work is how tightly it has to synchronize with regulatory submission timing, rather than follow it. Waiting until after regulatory approval to start building a value dossier generally means a damaging delay between approval and actual market access — exactly the gap that erodes a launch's commercial window and can cost a company meaningfully in lost revenue during patent-protected exclusivity.

In the European Union, this synchronization pressure has become more structurally explicit with the EU's Health Technology Assessment Regulation, which introduced Joint Clinical Assessments run in parallel with, rather than strictly after, the centralized EMA approval process for certain product categories. The practical effect for market access teams is that dossier preparation now has to start earlier and move in closer lockstep with the regulatory submission than it typically did before, rather than beginning only once an approval decision is in hand. Parallel scientific advice procedures, where a company can seek simultaneous input from a regulatory agency and an HTA body on a development plan, reflect the same underlying shift toward earlier, more integrated market access planning.

This means the specialist in this role increasingly needs real fluency in regulatory submission timelines and milestones, not just HTA and payer requirements, simply to plan backward correctly from a launch date that depends on both processes landing in the right order.

Skills and Background That Actually Transfer Into This Role

There isn't one standard entry path, which makes this a role candidates sometimes undervalue their own fit for. People move into it from several directions:

• From regulatory affairs, usually clinical or CMC submission experience, bringing strong document management discipline and familiarity with how clinical data gets packaged for a technical reviewing body — the biggest gap to close is health economics literacy.
• From HEOR or health economics consulting, bringing strong comparative-effectiveness and economic modeling fluency — the biggest gap to close is operational submission management and cross-jurisdictional regulatory timeline awareness.
• From pricing and reimbursement consulting firms, where many people build early exposure to multiple countries' HTA requirements before moving in-house to a single sponsor.
• From medical affairs or medical writing, particularly people with strong experience translating complex clinical evidence into clear, audience-specific narratives — a core skill this role leans on constantly.
• From within a commercial or market access analyst team, where people have already been exposed to payer landscape research and competitive pricing intelligence and are looking to move from supporting the submissions process into owning a piece of it directly.

It's worth being honest that titles in this space are inconsistent across companies, which makes the job search itself part of the challenge. A posting for "Global Value Dossier Lead," "Market Access Submissions Manager," "HEOR and Market Access Liaison," or even "Pricing and Reimbursement Strategist" can describe substantially overlapping work. Reading the actual responsibilities section of a posting, rather than relying on the title alone, is usually the only reliable way to tell whether a given role sits closer to the submissions-and-process side of the work or closer to pure economic modeling.

Whatever the starting point, the strongest candidates tend to show genuine comfort moving between two different technical vocabularies in the same conversation — clinical trial design on one side, health economic modeling assumptions on the other — without needing either one translated for them first.

What a Typical Week Looks Like

The day-to-day work is less glamorous than the stakes behind it might suggest, and it's worth describing plainly for anyone considering the move. A meaningful share of the week goes into project management: tracking which country-specific dossier sections are drafted, reviewed, or still waiting on an HEOR model update, and chasing the people who own each piece. Another chunk goes into translation work in the literal sense — rewriting the same underlying clinical finding three or four different ways so it answers a UK HTA reviewer's cost-effectiveness question, a US payer's budget-impact question, and a German reviewer's additional-benefit question without ever contradicting itself across documents. There's also a steady stream of internal stakeholder management: keeping medical affairs, HEOR, regulatory, and commercial teams aligned on a single evolving value narrative, even when each function has its own version of what matters most about the product. None of this is reflected in headlines about a drug launch, but all of it determines whether the launch actually reaches patients on schedule.

Conclusion

Market access submissions work sits at a genuinely underappreciated pressure point in the life sciences launch sequence: the place where clinical and regulatory success gets converted, or fails to get converted, into actual patient access and commercial return. It rewards people who are comfortable being bilingual across clinical evidence and health economics, and who can manage a multi-country, multi-stakeholder submission process without losing the thread. As HTA requirements tighten and synchronize more closely with regulatory timelines, particularly in Europe, demand for people who can do this work well is likely to keep building — quietly, the way this role has always operated.